This dataset contains the summary data visualizations and clinical data of IMPACT sequencing of 229 cell-free DNA (cfDNA) and associated tumor samples with matched normal from 118 patients. Clinical data includes: Cancer Type, Number of Samples Per Patient, Mutation Count, Fraction Genome Altered, Sex, Primary/Metastasis Sample Type, Collaboration Id, Gene Panel, Oncotree Code, Tumor/cfDNA Sample...

Summary from GEO: "In lung and prostate adenocarcinomas, neuroendocrine (NE) transformation to an aggressive derivative resembling small cell lung cancer (SCLC) is associated with poor prognosis. We previously described dependency of SCLC on the nuclear transporter exportin 1. Here we explored the role of exportin 1 in NE transformation. We observed upregulated exportin 1 in lung and prostate pre-transformation...

Summary from GEO: "To investigate the effects of loss of LSD1 (KDM1A) on differential gene expression, we treated two cell lines of small cell lung cancer with 1uM LSD1 inhibitor ORY-1001 or vehicle control for 10 days. We then performed gene expression profiling analysis on treated and control cells for each of the two cell lines." Overall design from GEO: "Comparative gene expression profiling...

Description from Figshare: "Supplementary Figure 1: Example of KRAS-mutated LCNEC: Illustration of NGS and histopathologic features; Supplementary Figure 2: Dot plots for total number of genomic alterations in carcinoid-like vs other LCNECs; Supplementary Figure 3: OncoPrints for chromatin modifier, neurogenesis/neural function, DNA replication/repair and PI3K-AKT-mTOR pathway genes; Supplementary...

Description from Figshare: "Supplementary Table 4: Complete list of mutations and copy number alterations detected by MSK-IMPACT in 45 LCNECs"

Description from Figshare: "Supplementary Table 5: Detailed summary of NOTCH gene family mutations"

Description from Figshare: "Supplementary Table 1: Next-generation sequencing (MSK-IMPACT) gene panel"

Description from Figshare: "Supplementary Table 6: Complete list of potentially-actionable alterations"

Description from Figshare: "Supplementary Table 2: Immunohistochemical antibodies and protocols"

Description from Figshare: "Supplementary Table 7: Detailed chemosensitivity data"